COMMUNIQUÉS West-GlobeNewswire

Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026
19/08/2026
Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026 Presentation will provide additional analysis from the Phase IIa study of RESP-X in Pseudomonas aeruginosa -colonised [...]
Nasus Pharma Announces Transition of Chief Financial Officer
19/08/2026
TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative [...]
Kynexis Extends Series A to €97 Million to Advance Potential First-in-Class Investigational Medicine for Cognitive Disorders
19/08/2026
Novartis Venture Fund joins Kynexis’ existing investor syndicate, supporting the Company’s vision of becoming a leading late-stage cognition company Financing supports Phase 2 close-out activities and preparation for [...]
Grey Matters Retains Nationally Recognized ProScan to Read Brain Images from its Flagship NovaScan Neuroimaging Clinics™ Location in Florida
19/08/2026
VANCOUVER, British Columbia, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “ Company” or “ Grey Matters ”) (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to [...]
Lungpacer Medical Nominated for 2026 Prix Galien USA Award for Best Medical Technology
19/08/2026
Nomination by the Prix Galien Foundation recognizes the AeroPace® System, the first FDA-approved diaphragm neurostimulation therapy to help critically ill patients breathe on their own again EXTON, Pa., Aug. 19, 2026 ( [...]
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease
19/08/2026
MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to [...]
Avicanna Announces Closing of Strategic Non-Brokered Private Placement
19/08/2026
Strategic investment by pharmaceutical executive and life sciences investor Michael Porter TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a [...]
SK pharmteco célèbre l’avancement des travaux par une cérémonie d’inauguration de deux sites de production de pointe sur son campus de Swords, en Irlande
19/08/2026
L’événement souligne une importante augmentation de la capacité de production commerciale d’API de petites molécules et l’ouverture d’une nouvelle unité de production à l’échelle du kilogramme, conforme aux BPF, dédiée [...]
Applied Biologics Welcomes CMS’ Continued Commitment to Clinical Evidence in Advanced Wound Care
19/08/2026
Applied Biologics believes continued investment in high-quality clinical research is essential to advancing patient care SCOTTSDALE, Ariz., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical [...]
Sofwave Surpasses One Million Treatments Worldwide; Milestone Treatment Performed in South Korea
19/08/2026
Global milestone reflects sustained physician utilization, patient adoption and the expanding reach of Sofwave’s SUPERB™ technology SAN CLEMENTE, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd. (TASE: [...]
Atsena Therapeutics Appoints Matt Pauls to Board of Directors
19/08/2026
Matt Pauls brings more than 25 years of biopharma leadership and rare disease clinical development and commercial expertise as Atsena advances its ocular gene therapy pipeline toward commercialization DURHAM, N.C., Aug [...]
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
19/08/2026
– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes – – Publication provides peer-reviewed validation for V007 Phase 3 data [...]
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
19/08/2026
WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
19/08/2026
- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed - Preliminary [...]
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
19/08/2026
ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
19/08/2026
Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected by year-end RA is a $24 billion market with [...]
Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth
19/08/2026
Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year 502 active [...]
NOMAD Achieves UL 9540 Certification for 1 MW Transportable Battery Energy Storage System
19/08/2026
Certified Traveler system supports resilient power deployment for Missanabie Cree First Nation in Northern Ontario, Canada BOCA RATON, Fla., Aug. 19, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions Inc. ("NOMAD" or the " [...]
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
19/08/2026
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation NDA acceptance is supported by positive Phase 3 data, which were published in JAMA Neurology, and Phase 2b [...]

Pages